Brokerages Expect Heron Therapeutics Inc (HRTX) Will Announce Earnings of -$0.48 Per Share

Share on StockTwits

Wall Street analysts forecast that Heron Therapeutics Inc (NASDAQ:HRTX) will post earnings of ($0.48) per share for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Heron Therapeutics’ earnings. The lowest EPS estimate is ($0.60) and the highest is ($0.29). Heron Therapeutics posted earnings of ($0.77) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 37.7%. The business is expected to issue its next quarterly earnings report on Monday, November 5th.

According to Zacks, analysts expect that Heron Therapeutics will report full-year earnings of ($2.22) per share for the current year, with EPS estimates ranging from ($2.56) to ($1.86). For the next financial year, analysts expect that the business will report earnings of ($0.59) per share, with EPS estimates ranging from ($1.48) to $0.45. Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that cover Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Wednesday, August 8th. The biotechnology company reported ($0.54) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.68) by $0.14. The firm had revenue of $17.28 million for the quarter, compared to the consensus estimate of $12.82 million. Heron Therapeutics had a negative net margin of 411.41% and a negative return on equity of 112.35%. The company’s revenue was up 103.1% on a year-over-year basis. During the same period last year, the firm posted ($0.80) EPS.

A number of research analysts recently commented on HRTX shares. Cowen reaffirmed a “buy” rating and issued a $48.00 target price on shares of Heron Therapeutics in a research report on Tuesday, May 8th. Cantor Fitzgerald set a $40.00 price target on shares of Heron Therapeutics and gave the stock a “buy” rating in a research note on Thursday, May 10th. Oppenheimer set a $34.00 price target on shares of Heron Therapeutics and gave the stock a “buy” rating in a research note on Thursday, May 10th. BidaskClub cut shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 11th. Finally, ValuEngine upgraded shares of Heron Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 2nd. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $50.09.

In other news, CEO Barry D. Quart sold 50,000 shares of the firm’s stock in a transaction on Thursday, June 21st. The shares were sold at an average price of $39.05, for a total value of $1,952,500.00. Following the completion of the sale, the chief executive officer now owns 69,600 shares in the company, valued at approximately $2,717,880. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Robert Rosen sold 129,469 shares of the firm’s stock in a transaction on Friday, June 29th. The stock was sold at an average price of $39.59, for a total transaction of $5,125,677.71. Following the completion of the sale, the president now owns 132,109 shares of the company’s stock, valued at approximately $5,230,195.31. The disclosure for this sale can be found here. Insiders sold a total of 440,469 shares of company stock valued at $17,218,958 in the last 90 days. Company insiders own 16.20% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Quantbot Technologies LP acquired a new stake in shares of Heron Therapeutics in the 1st quarter worth $117,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Heron Therapeutics in the second quarter valued at about $151,000. SG Americas Securities LLC acquired a new stake in shares of Heron Therapeutics in the first quarter valued at about $183,000. NewSquare Capital LLC acquired a new stake in shares of Heron Therapeutics in the second quarter valued at about $211,000. Finally, Credit Agricole S A acquired a new stake in shares of Heron Therapeutics in the first quarter valued at about $240,000.

NASDAQ HRTX opened at $39.55 on Thursday. The firm has a market capitalization of $2.99 billion, a P/E ratio of 10.84 and a beta of 1.56. Heron Therapeutics has a 12 month low of $14.40 and a 12 month high of $42.90.

About Heron Therapeutics

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Featured Article: Hedge Funds – How They Work For Investors

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply